DR58 DataRelease
Release Date: October 2025
New Studies: 25
Updated Studies: 1
New Studies
| SDY3173: Sequential immunization with chimeric hemagglutinin del-NS1 attenuated influenza vaccines induces broad humoral and cellular immunity | |||||||||
| Status: | New | ||||||||
| Description: | Mice were intranasally administered cH8/1-del-NS1 followed by a cH11/1-del-NS1 heterologous booster, then challenged with seasonal H1N1 influenza virus and heterologous highly pathogenic avian H5N1. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3QJKM5VTT | ||||||||
| Subjects: | 223 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY3185: Immune responses to fetal surgery | |||||||
| Status: | New | ||||||
| Description: | Maternal mononuclear cells from baseline, POD14, and delivery from women who underwent fetal surgery compared to those who did not were blocked with Fc blocking antibody (Biolegend, San Diego, CA) before being stained with viability dye and 14 monoclonal antibodies specific for T cell subtypes. Flow cytometry data was acquired on a LSRFortessa X-20 (BD Biosciences) using a standardized protocol. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3A0XATCHK | ||||||
| Subjects: | 12 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY3190: SAM COBRA vaccine antibody response to influenza | |||||||
| Status: | New | ||||||
| Description: | The use of self-amplifying mRNA (SAM) vaccines that express COBRA-HA proteins are used to create a more effective seasonal flu vaccine. Mice and ferrets were vaccinated with the SAM COBRA-HA vaccine, and sera samples were collected after. Hemagglutination assays (HAI) and viral plaque assays were used to evaluate antibody response to the virus. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3XNZULSWC | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3191: A clade 2.3.4.4b H5N1 virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins | |||||||
| Status: | New | ||||||
| Description: | This study assessed a low-dose inactivated split virus vaccine derived from clade 2.3.4.4b H5N1, formulated with an Alum/CpG adjuvant, using a preclinical mouse model. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M349W2IR3X | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3194: Long-lasting B cell convergence to broadly reactive epitopes after chimeric HA vaccination | ||||||||||
| Status: | New | |||||||||
| Description: | The authors determine the specificity/function of B cells induced by cHA vaccination | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M35TFIHI2J | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| SDY3195: Comparisons of CD4+ T cells, serological responses and antibody titers against SARS-CoV-2 Variants | ||||||||||
| Status: | New | |||||||||
| Description: | This study investigated immune response among individuals from different ethnic groups approximately two years following administration of a third dose of COVID-19 vaccine (BNT162b2, mRNA-1273, ChAdOx1, or BBIBP-CorV). A total of 44 participants were assessed using spectral flow cytometry, ELISA, and pseudotyped virus neutralization assays. Measurements included Spike-specific CD4+ and CD8+ T cell responses, receptor-binding domain IgG antibody titers, and neutralizing antibody levels. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3ID11R70I | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| SDY3198: An early burst of IL-2 synthesis influences CD8 T cell fates | |||||||
| Status: | New | ||||||
| Description: | The differentiation of CD8 T cells into effector and memory populations is guided by a combination of antigenic, costimulatory, and cytokine signals. Here we show that, within 24 hours of activating naïve CD8 T cells, populations emerge with divergent patterns of IL-2 and IFN-g synthesis. This rapid, dynamic, and heterogeneous burst of cytokine production manifests with every CD8 T cell specificity analyzed, is apparent in vivo and in vitro, and occurs prior to the first cell division. Nevertheless, how the intrinsic manufacture of distinct cytokines forecasts and influences the properties and fates of the producer cell itself are not well defined. We demonstrate that the initial cell intrinsic synthesis of IL-2 attenuates IL-2-dependent STAT5 signaling, but that this is not due to differences in the surface expression of the IL-2 receptor complex. The functionally discrete subsets are transcriptionally distinct and display differences in the expression of hallmark effector and memory associated genes. Using cytokine reporter systems, we reveal that these early functional differences are consequential for establishing fate biases and directing the gain of effector and memory T cell properties. The bifurcation between the abilities of IL-2-producing and non-producing subsets to elaborate STAT5 signaling is consistent with a model in which non-IL-2-producing CD8 T cells are more receptive to extrinsic IL-2 signals and preferentially contribute to the early surge of effector formation. Despite this, both IL-2-producing and non-producing CD8 T cells can go on to acquire memory traits, indicating that there is developmental diversity within each cytokine producing subset. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3S66DBQCC | ||||||
| Subjects: | 152 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY3219: Analysis of CK1 inhibition effects on immune system in healthy and CLL-bearing mice | ||||||||||||||||||||||||||||
| Status: | New | |||||||||||||||||||||||||||
| Description: | Casein kinase 1 (CK1) has been proved as an efficient approach in the treatment of chronic lymphocytic leukemia (CLL), as the usage of PF-670462 as the therapeutic agent led to longer overall survival and scarcer relapse in Eµ-TCL1 adoptive transfer (AT) mouse model. In our follow-up study, we focused on elucidation of the mechanisms leading to this very promising effect and one of our key biological questions was whether the CK1 inhibition modulates the microenvironment of CLL in vivo and in what favor. Thus, we conducted several in vivo experiments on both healthy C57BL/6J mice (treated daily by peroral gavage for 2 weeks) and on C57BL/6J mice upon AT of CLL cells from Eµ-TCL1 donors (again, the recipient mice were treated daily by peroral gavage for 5-8 weeks - the endpoint was dependent on the speed by which the control group of mice developed terminal stage of CLL-like disease). Then, during the endpoint, we performed flow cytometric analysis focused on selected immune cell populations (NK cells, healthy and leukemic B cells and various subsets of CD4+ and CD8+ T cells), the relative abundances of which were inspected in 4 different types of microenvironment - peripheral blood (PB), lymph nodes (LN), spleen (SPL) and bone marrow (BM). The data from healthy and CLL-bearing mice were merged to the same analysis, so that we would be able to distinguish the effects CK1 inhibition from the CLL suppression. Our main aim was to inspect whether CK1 inhibition in vivo results in changes in CLL microenvironment that might contribute to CLL suppression and at the same time, whether this promising therapeutic agent isn't by any chance connected to severe changes in immune cell composition, which might lead to immunotoxicity and thus, lower the potential of this agent in the clinics. | |||||||||||||||||||||||||||
| Program/Contract: |
|
|||||||||||||||||||||||||||
| DOI: | 10.21430/M3AW1A5E9X | |||||||||||||||||||||||||||
| Subjects: | 0 | |||||||||||||||||||||||||||
| Study PI, contact: |
|
|||||||||||||||||||||||||||
| Publications: | None | |||||||||||||||||||||||||||
| Resources: |
|
|||||||||||||||||||||||||||
| Assays: | None | |||||||||||||||||||||||||||
| Clinical Assessments: | None | |||||||||||||||||||||||||||
| SDY3220: Analysis of the response of in vitro proliferating CLL patient cells to CK1 inhibition | |||||||||||||||||||
| Status: | New | ||||||||||||||||||
| Description: | Casein kinase 1 (CK1) has been proved as an efficient approach in the treatment of chronic lymphocytic leukemia (CLL), as this therapeutic strategy led to longer overall survival and scarcer relapse in Eµ-TCL1 adoptive transfer (AT) mouse model. In this study, we aimed to further characterize what mechanism makes CK1 inhibition efficient in counteracting the CLL progression. In particular, we performed bulk RNA sequencing on splenic CLL cells from in vivo treated Eµ-TCL1 AT mice which led us to a hypothesis that CK1 inhibition delays the cell cycle progression of the CLL cells by accumulation of cells at the S/G2 interface. To be able to test whether this mechanism might lead to actual attenuation of primary CLL cells, we utilized an established protocol that uses CD40L-expressing HS5 stromal cells in combination with soluble interleukin (IL-) 4 and IL-21 in order to supply the follicular T helper cell-mediated signals in the microenvironment of the CLL cells and lead to CLL cell activation and proliferative burst. As this experimental approach is very well suitable for testing of compounds, we utilized it to test whether the CK1 inhibition (using commercially available PF-670462 and more selective in-house inhibitor MU1742) would counteract the proliferative burst of the primary CLL cells which came as a result of microenvironmental stimulation. This helped us to test intrinsic and microenvironmental aspect of the mechanism-of-action of the CK1 inhibition in one well. The provided data are a result of the 6 day in vitro co-culture of primary CLL cells with the CD40L+ HS5 stromal cells along with the treatment, where the dose of the fresh soluble IL-4 and IL-21 along with the inhibitors was again supplied on day 3 of the co-culture (for more detailed information, see the protocol or attached publications). The cohort includes 35 patients in total, 21 of them have been tested on both CK1 inhibitors. Since the cohort displayed heterogeneous response to the treatment with CK1 inhibitors and even included a minority of samples resistant to the treatment, we next gathered used multiple clinical parameters to further characterize the resistant group of sanples and correlate the response to the known clinical parameters (provided in anonymized form). All samples from the peripheral blood of the CLL patients were taken after signature of informed consent approved by the Ethical Committee of the University Hospital Brno in accordance with the Declaration of Helsinki. | ||||||||||||||||||
| Program/Contract: |
|
||||||||||||||||||
| DOI: | 10.21430/M38W4KXGPP | ||||||||||||||||||
| Subjects: | 0 | ||||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||||
| Publications: | None | ||||||||||||||||||
| Resources: |
|
||||||||||||||||||
| Assays: | None | ||||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||||
| SDY3225: Flow cytometric analysis of NFκB in primary CLL cells upon co-culture with M2-10B4 stromal cells | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Casein kinase 1 (CK1) has been proved as an efficient approach in the treatment of chronic lymphocytic leukemia (CLL), as this therapeutic strategy led to longer overall survival and scarcer relapse in Eµ-TCL1 adoptive transfer (AT) mouse model. In this study, we aimed to describe the mechanism-of-action of the CK1 inhibition on the primary CLL cells that were due to their low viability in vitro stimulated by co-culture with M2-10B4 stromal cells that provide activation stimuli mimicking the microenvironment of the lymph nodes (LN). Based on our RNAseq experiment originating from this co-culture model (with addition of treatment by 10µM PF-670462), we were able to see significant downregulation of multiple activation-related pathways in the CLL cells upon CK1 inhibition. One of the main hits was the NFκB signalling pathway which showed decreased activity score based on the PROGENy tool in R. Due to this significant effect on gene expression level, we wanted to inspect whether the NFκB is downregulated also on the protein level, for which we utilized the same experimental design with the flow cytometric detection of intracellular NFκB in primary CLL cells that was performed at the endpoint. The provided FCS files originate from 7 CLL patient samples that underwent this experimental set-up. In case of all the patients, both the comparison between non-treated and treated cells from CLL cell mono-culture and CLL cell co-culture with M2-10B4 stromal cells have been done. All samples from the peripheral blood of the CLL patients were taken after signature of informed consent approved by the Ethical Committee of the University Hospital Brno in accordance with the Declaration of Helsinki. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M37XJESOQJ | ||||||||||||
| Subjects: | 0 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: | None | ||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY3230: Protection against reinfection with Mycobacterium tuberculosis extends across heterologous Mtb lineages | |||||||
| Status: | New | ||||||
| Description: | Immunological memory elicited either through previous or ongoing M. tuberculosis (Mtb) infection provides a critical mechanism by which hosts protect against re-infection and disease progression upon Mtb re-exposure. Conversely, the global circulation of—and uneven competition between—distinct Mtb strains suggest certain bacterial clades are able to better spread across communities, potentially by evading memory responses gained by prior infection with genomically different strains. To address this question, we conducted a heterologous reinfection study in cynomolgus macaques involving primary infection by a Lineage 4 Erdman Mtb strain and subsequent re-infection by a Lineage 2 strain (L2-HT), which belongs to a clade that has been epidemiologically shown to be successfully spreading over the last decade in Lima, Peru cohort. Here, through microbiologic, PET-CT and sequencing of Mtb genomic barcodes, we show that reinfected animals developed fewer lung lesions and controlled both pulmonary and disseminated forms of disease better than naïve animals that have had no prior exposure to Mtb. Thus, protection against reinfection is not limited by Mtb lineage, providing optimism that vaccines can be effective across populations and geographic locations. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3UDKB7YI5 | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3259: TLR4 or TLR7/8 agonists adjuvanted COBRA HA vaccines | |||||||
| Status: | New | ||||||
| Description: | The protective efficacy against a panel of influenza viruses and immune responses was evaluated in mice vaccinated with COBRA HA and two different TLR adjuvants. The study tested various formulations of TLR4 agonist, INI 2002, and the TLR 7/8 agonist, INI 4001, mixed with a computationally optimized H1 HA antigen (COBRA) Y2, with the goal of identifying the most effective formulation for eliciting high-titer protective antibodies. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3ZD77YCIE | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3264: Group 1 and group 2 hemagglutinin stalk antibody response according to age | |||||||
| Status: | New | ||||||
| Description: | The authors investigate the induction of HA stalk-specific antibodies after seasonal influenza vaccination, considering the age of the cohorts. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3L93KEP44 | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3266: Impact of age and prior COVID-19 on the response to influenza A components in the 2020-2021 Fluzone vaccine. | |||||||
| Status: | New | ||||||
| Description: | The authors assessed participants' humoral responses to the influenza A components analyzed in relation to age and COVID-19 history, post Fluzone vaccination, 2020-2021 season. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M38TQTBVMV | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3270: Interferon mediated prophylactic protection against respiratory viruses | |||||||
| Status: | New | ||||||
| Description: | The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (delta-NS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-specific humoral and cellular adaptive immune responses. Attenuation of delta-NS1 influenza viruses is due to their high IFN inducing properties, that limit their replication in vivo. This study demonstrates that pre-treatment with a delta-NS1 virus results in an antiviral state which prevents subsequent replication of homologous and heterologous viruses, preventing disease from virus respiratory pathogens, including SARS-CoV-2. Our studies suggest that delta-NS1 influenza viruses could be used for the prophylaxis of influenza, SARS-CoV-2 and other human respiratory viral infections | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3RQR8K8PR | ||||||
| Subjects: | 172 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: |
|
||||||
| SDY3275: Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Although vaccines effectively prevent coronavirus disease 2019 (COVID-19) in healthy individuals, they appear to be less immunogenic in individuals with chronic inflammatory disease (CID) or receiving chronic immunosuppression therapy. Therefore, here, we assessed antibody responses of a cohort of individuals with CID. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3SA0J3G43 | ||||||||||||
| Subjects: | 100 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY3278: Serological response to the quadrivalent influenza vaccine. | |||||||
| Status: | New | ||||||
| Description: | Identification of novel molecular markers of the vaccine response and evaluation of serological response in adults and children via age, BMI, sex, race,and comorbidities using computational model. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3MT9B2J3T | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3279: Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections | ||||||||||
| Status: | New | |||||||||
| Description: | The authors compare type-specific B cell responses in unvaccinated/vaccinated individuals with Delta and Omicron BA.1 SARS-CoV-2 variant infections. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3CS3YI19U | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| SDY3280: Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells | |||||||
| Status: | New | ||||||
| Description: | Here, we report how routes of immunization in mice influence influenza-specific cell mediated and humoral immunity. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3V79LR0MA | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3281: Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach. | |||||||
| Status: | New | ||||||
| Description: | Linear mixed effects models were used to evaluate symptoms experienced by COVID-positive participants during natural infection and following SARS-CoV-2 mRNA vaccination | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3W2M30RIR | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3282: cGAMP Microparticles Affect the Immunogenicity of Influenza mRNA Vaccine | |||||||
| Status: | New | ||||||
| Description: | Evaluation of the immune response in mice by administering COBRA mRNA-LNPs and Polymeric cGAMP Microparticle vaccine formulations and measuring antibody production and protection against lethal influenza challenge. Additionally, in vitro assays were conducted to assess how the STING agonist affected mRNA translation. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3Q3DP8MD4 | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3283: Neutralizing antibodies and IgG4 subclass switching following vaccination with Covid-19 mRNA vaccines does not reduce infections | ||||||||||
| Status: | New | |||||||||
| Description: | A longitudinal study comparing humoral immune responses in SARS-CoV-2 naive and previously infected individuals after a two-dose mRNA vaccine and booster. Anti-spike RBD IgG levels, neutralizing antibody titers against Wuhan-Hu-1 and Omicron BA.1, and IgG subclass distributions were measured over time. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3QE4VCMVY | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| SDY3287: Mice with diverse microbial exposure histories | |||||||||||
| Status: | New | ||||||||||
| Description: | Laboratory mice comprise an expeditious model for preclinical vaccine testing; however, vaccine immuno-genicity in these models often inadequately translates to humans. Reconstituting physiologic microbial experience to specific pathogen-free (SPF) mice induces durable immunological changes that better recapitulate human immunity. We examined whether mice with diverse microbial experience better model human responses post vaccination. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3XP9KEKT4 | ||||||||||
| Subjects: | 592 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: |
|
||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| SDY3295: Long-term, infection-acquired immunity against Delta variant | ||||||||||
| Status: | New | |||||||||
| Description: | Here, we use a live virus neutralization assay with sera from Pfizer- and Moderna-vaccinated individuals to examine neutralizing antibody titers against SARS-CoV-2 and observe a 3.9- and 2.7-fold reduction, respectively, in neutralizing antibody titers against the Delta variant compared with an early isolate bearing only a D614G substitution in its spike protein. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3Z1Z3Y9AK | |||||||||
| Subjects: | 91 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| SDY3301: Proteomic signatures | |||||||
| Status: | New | ||||||
| Description: | Measuring proteomic signatures in UGA cohort 2019- 2020 season | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3JVF5RTPG | ||||||
| Subjects: | 151 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
Updated Studies
| SDY1760: Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients with COVID-19 | ||||||||||||||||
| Status: | Updated | |||||||||||||||
| Description: | This is a prospective observational cohort of adult participants hospitalized with known or presumptive COVID-19. | |||||||||||||||
| Program/Contract: |
|
|||||||||||||||
| DOI: | 10.21430/M3FCC2J1RF | |||||||||||||||
| Subjects: | 0 | |||||||||||||||
| Study PI, contact: |
|
|||||||||||||||
| Publications: |
|
|||||||||||||||
| Resources: |
|
|||||||||||||||
| Assays: | None | |||||||||||||||
| Clinical Assessments: | None | |||||||||||||||